Schedule & Agenda

Full schedule & agenda from the 2019 BIO International Convention.

2019 Schedule & Agenda

Below is a complete list of the programming and events from the 2019 BIO International Convention. Stay tuned for announcements about the 2020 BIO International Convention schedule and agenda in March 2020.

BIO International Convention
Date
  • Show All
Time
  • Show All
  • Show All
  • Show All
Company Type
  • Show All
Main Therapeutic Focus
  • Show All
Development Phase of Primary Product
  • Show All
Jump to Day
126 Results
Monday, June 3
1:00 PM - 2:15 PM
In May, the Trump Administration issued its “American Patients First” drug pricing blueprint, aimed…
For some patients with no hope, the potential of gene therapy represents a light at the end of the…
Last year, Immuno-oncology (I/O) drove nearly 30% of licensing activity in Oncology while half of…
The expansion of new drug modalities and growth of precision medicine create new challenges and…
As noted in the BRAIN 2025 report, the burden of human brain disorders is significant. Over five…
Over the past three decades, Congress and the FDA have put in place several programs to drive…
1:15 PM - 1:45 PM
Chris has spent his career in the Senate focused on working across the aisle to get things done for…
2:30 PM - 3:45 PM
Academic science is arguably the greatest source of innovation in our ecosystem, yet faces…
As healthcare shifts towards digital, the spotlight is shining on the emerging field of Digital…
Developments in biologics are of ever-increasing focus in drug development. Unlike more traditional…
Current investment in antimicrobial R&D is insufficient to address growing resistance. US…
Our industry has been shaped by an ever-changing landscape, with emerging science disrupting the…
What you have to say in 30 seconds could mean the difference between a meeting with an investor…
At the Biomedical Advanced Research and Development Authority, BARDA, We are innovating not only in…
Scientific technology for gene therapy has made tremendous progress and the regulatory landscape is…
2:30 PM - 4:45 PM
Join us for a viewing of the movie 'Turning Point' and a discussion with advocates and researchers,…
4:00 PM - 5:00 PM
Digital health technologies are increasingly being used for drug discovery, development, evidence…
We have all heard the statistics - 19% of clinical trials terminate due to failed recruitment or…
Despite advances in many drug research paradigms - DNA sequencing, high throughput screening and…
At the NIH, SBIR/STTR spending limits have increased to more than $1B in 2018. SBIR eligibility…
With the recent approvals of gene therapies and more on the horizon, panelists will look to explore…
Reproducibility is a foundational element of the scientific method, a benchmark upon which the…
One of the unique challenges affecting the development of new vaccines and therapeutics against…
The Biologics Price Competition and Innovation (BPCIA) was passed as part of the Affordable Care…
Tuesday, June 4
11:00 AM - 12:15 PM
This session will showcase new scientific and clinical data on novel vaccines and immunotherapies…
Globally, about 17 million people suffer a stroke each year, more than all dementias combined,…
Women graduate college at higher rates than men and make up nearly half the US workforce, yet only…
Recently, we have seen strong progress in the application of gene therapy for rare diseases,…
With healthcare becoming more and more personalized, industry stakeholders are looking for new ways…
The petrochemical industry spent the better part of the 20th century perfecting distillation for…
Too many emerging technologies get lost in translation, so new models are needed to help academic…
Drug overdose deaths including those involving opioids has continued to increase, reaching 42,000…
The requirements for patenting life science inventions under the European Patent Convention (EPC)…
In recent years, there’s been a scarcity of high quality, revenue-generating biopharma assets. This…
Value-based payment (VBP) arrangements, which align payments to observed value and outcome in a…
Attracting even 1% of the $200B annualized global biopharmaceutical investment may translate into …
How do you develop the right leadership and organizational capabilities that will enable your…
2:00 PM - 3:00 PM
In the fall of 2018 Congress passed the Substance Use-Disorder Prevention that Promotes Opioid…
Leading industrial biotech firms will discuss transformations in health and wellness stemming from…
Infectious Disease diagnostics face different fiscal pressures, economic considerations, and…
Research has a data problem. It is increasingly clear that there are issues with the robustness,…
All-time high valuations offer biopharma companies a window of opportunity to re-assess their…
In 2045, more than 50% of the US population will be Hispanic, Black, Asian and multiracial—up from…
Overcoming obstacles that hinder integration of real world data into current clinical development…
Join Wainwright Fishburn for a digital health market snapshot, followed by an in-depth discussion…
Emerging innovative companies in the pharma/biotech field face earlier generic competition than…
An investor once said, “You can replace an executive, but you can’t replace a founder.” Founders of…
Microbiome research is one of the hottest areas in biology, but do we really understand enough…
From human genome editing to cell and gene therapies, innovation in the biotechnology industry is…
Many pharma companies partner with diagnostic companies to develop, manufacture and commercialize…
2:00 PM - 3:30 PM
Ability to store, merge and analyze large volumes of data allows to introduce efficiencies into…
3:15 PM - 4:15 PM
There are more than 600 neurological disorders that impact millions of patients and families across…
We are beginning to understand the biological basis of aging and age-related diseases, making the…
The Supreme Court and the Federal Circuit Courts continue to issue opinions on a variety of hot IP…
Join us for a conversation with Peter Saltonstall, President and Chief Executive Officer at the…
The current biotech boom has conceived many innovative therapeutics, but we still lack an effective…
Valuing early-stage opportunities is challenging. Modeling will often provide a false sense of…
Patient engagement, although highly promoted across many health sectors, often lacks a clear…
The Opioid Crisis has had grave effects on both the public health and the well-being of our society…
This Session will discuss financing approaches for developing and commercializing innovative…
3:15 PM - 4:45 PM
Leading healthcare institutions in the Philadelphia region discuss how they are leveraging digital…
4:30 PM - 5:30 PM
Orphan Drug development has escalated at a rapid pace in recent years with over 500 products on the…
In recent years global innovation hubs and biomedical clusters have developed collaborative…
Oncology has always been one of the hottest research areas in pharma. As of August 2018, 40% of the…
The advent of patient-focused drug development has underscored the priority of engaging the patient…
The sun never sets on your patent portfolio! This session will circumnavigate the globe and provide…
Mind-body research began moving into the mainstream over a decade ago and it’s commonly understood…
Over the course of 2018 and 2019, the Food and Drug Administration (FDA) has proposed and…
Wednesday, June 5
11:00 AM - 12:00 PM
Spark Therapeutics commercially launched the first gene therapy for a genetic disease in the US and…
How is the biotech sector likely to be impacted by Brexit, both in the UK and the EU? This panel…
The session will address: • Why deprioritized compounds still offer the potential to help address…
Precision Medicine has helped transform cancer care from one-size-fits-all chemotherapy to a new…
There are thousands of genetic diseases for which there is no treatment. Genome editing is a…
This panel will provide insights on the distinct contributions of patient experience data and real…
A spirited debate, new and evolving methods, and a better appreciation of the role patients play…
This session will discuss the spectrum of technologies, both short and long term, that would help…
Potential benefits of Big Data applications in the field of pharmaceutical research is not only in…
The American Society of Clinical Oncology’s (ASCO) Annual Meeting brings together more than 30,000…
105AB, Level 100
11:00 AM - 12:15 PM
As care for lifestyle-driven chronic diseases expands in scope, prevention and recovery are…
Emerging company investment for drug development in highly prevalent chronic diseases is shown to…
1:45 PM - 2:45 PM
Cardiovascular-renal disease is the leading cause of death worldwide resulting in a massive…
Human gene editing continues to hold a major fascination within a biomedical and biopharmaceutical…
As larger biotech and pharmaceutical companies seek to expand or strengthen their product…
India has invested significant resources in erecting a biotechnology infrastructure from its…
Payers are evaluating provider and reimbursement policies, seeking value in precision health. This…
The impact of Machine Learning (ML) and Artificial Intelligence (AI) during the last decade has…
With multiple oncology "first launch" successes in recent years, most oncology emerging pharma…
105AB, Level 100
This session will focus on the scientific and clinical progress of novel platform technologies. …
A central challenge of rare disease drug development is not having enough patients to conduct…
How can big pharma bring the most value to new and innovative research and match the rapid pace of…
According to research from the US Health and Human Services, US tax payers pay 1.8 times the…
Since the first CAR T cell therapy was approved by the FDA in 2017, we’ve witnessed what was once…
3:00 PM - 4:00 PM
With drug pipelines slimming down in the face of complex and costly Phase IIIs and investors weary…
Increasingly, innovative medicines are coming to market introducing new modalities that are…
It is widely accepted that early cancer detection improves treatment options and increases 5-year…
105AB, Level 100
The science driving personalized medicine continues to push innovation in the advanced diagnostics…
Productive collaborations between biotech and major pharma provide a long-term competitive…
Genome editing offers the potential of new and effective treatments for genetic diseases. As…
The US is the global leader in ensuring patients have comprehensive access to the newest therapies…
Advances in genetics have altered the landscape for newborn screening, giving families new hope of…
Increased patient engagement in medicine development and regulatory approval decisions is occurring…
Artifical Intelligence (AI) is deeply impacting how biopharma companies operate in drug discovery…
While life sciences directed technology-based economic development (TBED) organizations have…
Cross-border collaboration between U.S. and Japan in the biopharma sector has intensified in recent…
4:15 PM - 5:15 PM
There is significant unmet need for new therapies for the treatment of depression. Only 29 active…
When children fall ill, they deserve to receive treatments that are both safe and effective. Yet 50…
Given the relatively high cost of rare disease treatments, payers play an increasingly important…
The march to make cancer a chronic condition is progressing but true success thus far has been…
This session addresses the landscape for regulatory approval of Laboratory Developed Tests (LDTs)…
Referencing European prices for Medicare Part B drugs is a possible approach for drug pricing…
Clinical trials are designed to measure for multiple endpoints including overall survival (OS),…
105AB, Level 100
Thursday, June 6
9:00 AM - 10:15 AM
Personalized Medicine in cancer care rests on the assumption that genomic profiling can aid in…
Biotechs working in early stage drug development are tapping into new sources of funding. Family…
As discovery and development of cancer drugs continues to explode, cost pressures continue to mount…
105AB, Level 100
There's no denying that investments and drug development in rare and orphan diseases have increased…
Artificial Intelligence (AI) is transforming virtually all sectors of modern society, including…
10:30 AM - 11:45 AM
Cell and gene therapies have the potential to change the therapy landscape in many therapeutic…
Even as the FDA and other government agencies have incentivized drug development for rare diseases,…
Digital Health innovation has the potential to transform patient care and lower healthcare costs…
This session will bring together traditional and corporate venture capitalists to share…
Head turning deals in precision medicine typically result in competitor companies analyzing every…
10:30 AM - 12:00 PM
India is looking to regulate cell and gene therapies as drugs. The panel of experts will discuss…
We have seen great strides in the approval of cancer immunotherapies, treatments that harness the…
105AB, Level 100